Literature DB >> 18516026

The societal benefit of nonprofit biotechnology companies.

Rena M Conti1.   

Abstract

Mesh：

Year:  2008        PMID： 18516026      PMCID： PMC4637938     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  5 in total

1.  Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.

Authors:  Victoria G Hale; Katherine Woo; Helene Levens Lipton
Journal:  Health Aff (Millwood)       Date:  2005 Jul-Aug       Impact factor: 6.301

Review 2.  Economics of new oncology drug development.

Authors:  Joseph A DiMasi; Henry G Grabowski
Journal:  J Clin Oncol       Date:  2007-01-10       Impact factor: 44.544

3.  Estimating the cost of new drug development: is it really 802 million dollars?

Authors:  Christopher P Adams; Van V Brantner
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

4.  Obstacles and opportunities in new drug development.

Authors:  K I Kaitin
Journal:  Clin Pharmacol Ther       Date:  2008-02       Impact factor: 6.875

5.  Market incentives and pharmaceutical innovation.

Authors:  Wesley Yin
Journal:  J Health Econ       Date:  2008-02-17       Impact factor: 3.883
  5 in total
  1 in total

Review 1.  Social Non-profit Bioentrepreneurship: Current Status and Future Impact on Global Health.

Authors:  Amir H Sadeghi; Charlotte Koldeweij; Grissel Trujillo-de Santiago; Milad Tannazi; Nikkie Hosseinnia; Oscar van Loosbroek; Amir Manbachi; Yannick J H J Taverne; Ad J J C Bogers; Mario Moisés Alvarez
Journal:  Front Public Health       Date:  2021-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.